Since our original work on the propagation of human trabecular cells for glaucoma research, we have been carefully monitoring potential alterations in the cells due to the in vitro environment. Limitations on the ability to repeatedly passage these cells without loss of mitotic potential and changes in morphology have prompted us to perform detailed evaluations of the ultrastructural features of individual trabecular cell lines to assure that the differentiated features of this cell type have been preserved. Cells from the younger patients and specialized growth factors appear particularly useful for biochemical and physiological studies of the normal properties of trabecular cells. Improved cell culture methodology may be essential to obtain suitable cultures of trabecular cells from patients with POAG and other sources which show a reduced mitotic potential. We plan to continue in our efforts to (1) define improved conditions for cell growth; (2) examine important physiological responses of the trabecular cells, such as phagocytosis and connective tissue production; and (3) evaluate the mechanisms by which glucocorticoids, prostaglandins, and cytochalasins may exert pharmacological effects on the outflow pathway. Quantitative assessment of cell division and electron microscopic observations will be employed in our studies of oxidative damage and other ;mechanisms of cell injury which may be related to the development of reduced outflow facility in POAG and aging. In addition, studies designed to evaluate the biochemical specificity of trabecular cells, including studies of cellular and cell surface proteins, cytoarchitecture, and the production and testing of monoclonal antibodies may add important new information. By comparing data obtained from cultured cells to that obtained from excised human trabecular tissue, we hope to better understand the prospects and limitations of the trabecular meshwork call culture system.

Agency
National Institute of Health (NIH)
Institute
National Eye Institute (NEI)
Type
Research Project (R01)
Project #
2R01EY002477-07
Application #
3256794
Study Section
Visual Sciences A Study Section (VISA)
Project Start
1979-04-01
Project End
1990-11-30
Budget Start
1985-12-06
Budget End
1986-11-30
Support Year
7
Fiscal Year
1986
Total Cost
Indirect Cost
Name
University of California San Francisco
Department
Type
Schools of Medicine
DUNS #
073133571
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Digicaylioglu, Murat; Garden, Gwenn; Timberlake, Sonia et al. (2004) Acute neuroprotective synergy of erythropoietin and insulin-like growth factor I. Proc Natl Acad Sci U S A 101:9855-60
Polansky, J R; Juster, R P; Spaeth, G L (2003) Association of the myocilin mt.1 promoter variant with the worsening of glaucomatous disease over time. Clin Genet 64:18-27
Polansky, Jon R (2003) Current perspectives on the TIGR/MYOC gene (Myocilin) and glaucoma. Ophthalmol Clin North Am 16:515-27, v-vi
Liu, X; Wu, Z; Sheibani, N et al. (2003) Low dose latrunculin-A inhibits dexamethasone-induced changes in the actin cytoskeleton and alters extracellular matrix protein expression in cultured human trabecular meshwork cells. Exp Eye Res 77:181-8
Filla, Mark S; Liu, Xuyang; Nguyen, Thai D et al. (2002) In vitro localization of TIGR/MYOC in trabecular meshwork extracellular matrix and binding to fibronectin. Invest Ophthalmol Vis Sci 43:151-61
Liu, Xuyang; Huang, Chun-Yuan; Cai, Suping et al. (2002) Transformation of human trabecular meshwork cells with SV40 TAg alters promoter utilization. Curr Eye Res 25:347-53
Fingert, John H; Stone, Edwin M; Sheffield, Val C et al. (2002) Myocilin glaucoma. Surv Ophthalmol 47:547-61
Lindsey, J D; Gaton, D D; Sagara, T et al. (2001) Reduced TIGR/myocilin protein in the monkey ciliary muscle after topical prostaglandin F(2alpha) treatment. Invest Ophthalmol Vis Sci 42:1781-6
Tamm, E R; Polansky, J R (2001) The TIGR/MYOC gene and glaucoma: opportunities for new understandings. J Glaucoma 10:S9-12
Colomb, E; Nguyen, T D; Bechetoille, A et al. (2001) Association of a single nucleotide polymorphism in the TIGR/MYOCILIN gene promoter with the severity of primary open-angle glaucoma. Clin Genet 60:220-5

Showing the most recent 10 out of 41 publications